MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)
Overview
The main reason for this study is to see how the study drug interacts with the body. It will compare different doses of the study drug with a drug already in use. Participants will be adults with liver disease that has affected the brain in the past.
Full Title of Study: “A Randomized, Open-Label, Phase 2a Comparator Study to Assess the Pharmacodynamics, Safety and Pharmacokinetics of Oral Administration MNK6106 (L-Ornithine Phenylacetate) Versus Rifaximin in Subjects With Hepatic Cirrhosis and a History of Prior Episodes of Hepatic Encephalopathy”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: July 14, 2020
Interventions
- Drug: MNK6106
- 1 gram tablet of MNK6106 for oral administration
- Drug: Rifaximin
- 550 mg tablet of rifaximin for oral administration
Arms, Groups and Cohorts
- Experimental: Group A: MNK6106 2 grams (tid)
- Participants receive 2 tablets of MNK6106 three times daily (tid) for 5 days
- Experimental: Group B: MNK6106 4 grams (bid)
- Participants receive 4 tablets of MNK6106 twice daily (bid) for 5 days
- Experimental: Group C: MNK6106 4 grams (tid)
- Participants receive 4 tablets of MNK6106 tid for 5 days
- Active Comparator: Group D: Rifaximin 550 mg (bid)
- Participants receive 1 tablet of rifaximin bid for 5 days
Clinical Trial Outcome Measures
Primary Measures
- Ammonia Plasma Levels at Baseline and Day 5
- Time Frame: Baseline, Day 5
- This test measures the level of ammonia in your blood. Ammonia, also known as NH3, is a waste product made by your body during the digestion of protein. Normally, ammonia is processed in the liver, where it is changed into another waste product called urea. Urea is passed from the body in urine. If your body cannot process or eliminate ammonia, a lab test of a blood sample shows it has built up in the bloodstream. High ammonia levels in the blood can lead to serious health problems, including hepatic encephalopathy.
Secondary Measures
- Number of Participants With Adverse Events by the End of the Trial
- Time Frame: within 15 days
- End of trial is defined as 7 (+/-3) days after last study treatment
Participating in This Clinical Trial
Key Inclusion Criteria:
A potential participant may only be included if (at screening), he/she: 1. Understands the study and has signed informed consent 2. Is an adult, not pregnant or lactating 3. Has cirrhosis of the liver 4. Has had 1 instance of HE within 12 months 5. Has hyperammonaemia defined as ≥37 μmol/L at screening Key Exclusion Criteria:
A potential participant will be excluded if (at screening), he/she: 1. Has contraindicated allergies 2. Expects liver transplant within 1 month 3. Has had a liver shunt within the last 3 months 4. Has inadequate kidney, gastrointestinal, or cardiac function 5. Has cancer, infection, lab abnormalities, or any other condition that, per protocol or in the opinion of the investigator might compromise: 1. the safety and well-being of the participant or potential offspring 2. the safety of study staff 3. the analysis of results
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 80 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Mallinckrodt
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Clinical Team Leader, Study Director, Mallinckrodt
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.